RCKT Rocket Pharmaceuticals Inc

Price (delayed)

$24.08

Market cap

$2.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.85

Enterprise value

$2.17B

Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it ...

Highlights
Rocket Pharmaceuticals's EPS has increased by 14% YoY and by 2.4% from the previous quarter
The quick ratio has increased by 30% since the previous quarter but it has declined by 6% year-on-year
The equity has declined by 10% since the previous quarter and by 3.8% year-on-year
RCKT's net income is down by 5% YoY

Key stats

What are the main financial stats of RCKT
Market
Shares outstanding
90.78M
Market cap
$2.19B
Enterprise value
$2.17B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$247.44M
EBITDA
-$239.76M
Free cash flow
-$209.7M
Per share
EPS
-$2.85
Free cash flow per share
-$2.24
Book value per share
$4.88
Revenue per share
$0
TBVPS
$4.65
Balance sheet
Total assets
$499.44M
Total liabilities
$57.94M
Debt
$25.95M
Equity
$441.5M
Working capital
$312.2M
Liquidity
Debt to equity
0.06
Current ratio
10.47
Quick ratio
10.08
Net debt/EBITDA
0.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-46.9%
Return on equity
-53.1%
Return on invested capital
-68.2%
Return on capital employed
-53%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RCKT stock price

How has the Rocket Pharmaceuticals stock price performed over time
Intraday
5.52%
1 week
6.78%
1 month
7.12%
1 year
30.37%
YTD
-19.65%
QTD
11.84%

Financial performance

How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$264.84M
Net income
-$249.31M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 9% YoY
RCKT's net income is down by 5% YoY

Growth

What is Rocket Pharmaceuticals's growth rate over time

Valuation

What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 14% YoY and by 2.4% from the previous quarter
The stock's price to book (P/B) is 27% more than its 5-year quarterly average of 3.9 and 10% more than its last 4 quarters average of 4.5
The equity has declined by 10% since the previous quarter and by 3.8% year-on-year

Efficiency

How efficient is Rocket Pharmaceuticals business performance
The ROIC has grown by 21% YoY
The return on assets is up by 5% year-on-year but it has declined by 2.2% since the previous quarter
RCKT's ROE is up by 4.7% YoY but it is down by 2.5% from the previous quarter

Dividends

What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCKT.

Financial health

How did Rocket Pharmaceuticals financials performed over time
Rocket Pharmaceuticals's current ratio has increased by 34% QoQ but it has decreased by 3.3% YoY
The quick ratio has increased by 30% since the previous quarter but it has declined by 6% year-on-year
The debt is 94% smaller than the equity
Rocket Pharmaceuticals's debt to equity has increased by 20% from the previous quarter
The equity has declined by 10% since the previous quarter and by 3.8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.